Congress Pharma SRL
Congress Pharma reported total assets of 82,571 € at the end of the 2025 financial year (annual accounts filed with the NBB on 16 Jul 2026).
The score of Congress Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +1326 % Total assets -84 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Congress Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 16 Jul 2026
- Year ended 31 Dec 2024filed on 02 Sep 2025
- Year ended 31 Dec 2023filed on 04 Oct 2024
- Year ended 31 Dec 2022filed on 29 Sep 2023
- Year ended 31 Dec 2021filed on 06 Sep 2022
Congress Pharma's financial analysis
- Solvency12.6%sector median: 32.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Congress Pharma
Congress Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0743.735.919
- VAT number
- BE0743735919
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SRL
- Incorporated
- 17 Feb 2020
- Registered office
- 1150 Woluwe-Saint-Pierre
- Latest accounts
- 2025 · filed on 16 Jul 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Congress Pharma (SRL) has been based in Woluwe-Saint-Pierre since 2020, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net loss of 301 € and equity of 10,393 €; its revenue is not published. Its solvency stands at 12.6%, below the median of its sector (32.3%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Congress Pharma
Companies in the same business, of comparable size and area, outside its group.
- Mandible Guide Research and experimental development on natural sciences and engineering Woluwe-Saint-Pierre · balance sheet 64,270 €
- Taikun Pharmaceutical Technology Manufacture of basic pharmaceutical products Ghent · balance sheet 275,396 €
- Loupi Medical Belgium Wholesale of pharmaceutical and medical goods Mont-Saint-Guibert · balance sheet 440,359 €
- SERGE HUGARD MANAGEMENT CONSULTING, en abrégé S.H.M.C. Wholesale of pharmaceutical and medical goods Mont-Saint-Guibert · balance sheet €1.67m
- Formac Pharmaceuticals Research and experimental development on natural sciences and engineering Leuven · balance sheet 2,112 €
- RevaTis Manufacture of pharmaceutical preparations Marche-en-Famenne · balance sheet €4.12m
- Hexacath Belgium Wholesale of pharmaceutical and medical goods Ixelles · balance sheet 96,025 €
- Linden API Wholesale of pharmaceutical and medical goods Ixelles · balance sheet 12,520 €
Frequently asked questions about Congress Pharma
What is the revenue of Congress Pharma?
Congress Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Congress Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0743735919 for Congress Pharma, if the company is VAT-registered. Its company number (CBE) is 0743.735.919.
Where is the registered office of Congress Pharma?
According to the CBE register, the registered office of Congress Pharma is in 1150 Woluwe-Saint-Pierre.
What is the equity of Congress Pharma?
At the close of the 2025 financial year, the equity of Congress Pharma amounts to 10,393 €, a solvency of 12.6% of total assets.
Who manages Congress Pharma?
The register lists 1 active mandates at Congress Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Congress Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →